This study is designed to learn about the efficacy and safety of an investigational medication called cagrilintide for weight loss. Paricipants will be randomly assigned to either cagrilintide or placebo with a 2 out of 3 chance of receiving the cagrilintide and a 1 out of 3 chance of receiving placebo. The study medication will be taken by injection once-weekly using a pen injector. The study starts with an in-person screening visit and then, if eligible, participants attend monthly visits to the site. The study last for 71 weeks (approximately 1.5 years) and will involve approximately 14 in-person visits at the clinic and 7 visits done by phone. Additionally, participants will meet with a dietitian every 4 weeks and would be asked to follow a reduced calorie diet and to work up to being physically active for at least 2.5 hours per week.

Who can Participate

Adults 18 and older with a BMI of 30 or higher OR a BMI of 27 or higher with high blood pressure, high cholesterol, sleep apnea or heart disease.

Study ID